RxDoctor Payments Data

Kristy Shafer, NP

Family · Mattoon, ILNPI 1306314778

Payments from drug & device makers

$7,842in general payments, 2019–2025

Across 385 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$851
  • Mallinckrodt Hospital Products Inc.$516
  • Supernus Pharmaceuticals, Inc.$422
  • Vanda Pharmaceuticals Inc.$389
  • Livanova USA, Inc.$379
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$6,94389%
  • Education$89911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,842 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$85,883
Medicare patients
298
Services billed
1,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam85$150,356
ZeposiaOzanimod Hydrochloride14$120,801
AubagioTeriflunomide12$108,623
AptiomEslicarbazepine Acetate39$98,851
QuliptaAtogepant38$43,354
TrudhesaDihydroergotamine Mesylate12$37,297
GocovriAmantadine Hcl16$35,342
UbrelvyUbrogepant27$30,041
Nurtec OdtRimegepant Sulfate12$21,756
Emgality PenGalcanezumab-Gnlm30$21,166
Aimovig AutoinjectorErenumab-Aooe22$16,600
Teriflunomide28$8,518
Memantine Hcl ErMemantine Hcl52$8,357
Modafinil20$8,314
Lamotrigine ErLamotrigine15$8,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$217$150,35685 claims
E.r. Squibb & Sons, L.L.C.Zeposia$22$120,80114 claims
Sunovion Pharmaceuticals Inc.Aptiom$121$98,85139 claims
AbbVieQulipta, Ubrelvy$1,354$73,39565 claims
Impel Pharmaceuticals Inc.Trudhesa$13$37,29712 claims
MDD US Operations, LLCGocovri$71$35,34216 claims
PfizerNurtec Odt$255$21,75612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Mattoon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →